SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?


To: Doc Bones who wrote (260)11/16/1999 7:03:00 AM
From: Doc Bones  Read Replies (1) | Respond to of 427
 
Interesting that AU fingered IDPH as a short Oct. 21, #3669, and posted negative info on it Sept. 9, #3063. AU (who "doesn't do biotech") has been with Avalon on LIPO, CLTR, and CLPA I believe.

The market hasn't been too kind to shorts lately. AU's planets were misaligned on Sept. 28 when he called major shorts on CIEN @ $38 (now $51) #3180, and PPRO @ $35 (now $116) #3183.

Doc



To: Doc Bones who wrote (260)11/21/1999 4:29:00 AM
From: Harold Conn  Read Replies (1) | Respond to of 427
 
The current Forbes has a discussion of Avalon and IDPH
in the Streetwalker column.

"... But the stock is overvalued ... sales will soon level
off ... next drug in the pipeline has limited potential ...."

forbes.com

Harold